IP Library › Granted Patent US 12,281,156
Granted Patent B2
US 12,281,156 · App. 17/933,725 · Granted Apr 22, 2025

Anti-respiratory syncytial virus antibodies, and methods of their generation and use

Inventor: Laura M. Walker (Lebanon, NH)
Assignee: Adimab, LLC
C07K16/1027A61K2039/505C07K2317/21C07K2317/33C07K2317/34C07K2317/565C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,281,156
App. No.
17/933,725
Granted
Apr 22, 2025
Kind
B2
Abstract

Anti-RSV antibodies with neutralizing potency against RSV subtype A and RSV subtype B are provided, as well as methods for their identification, isolation, generation, and methods for their preparation and use are provided.

Claims (71)

1. A pharmaceutical composition, comprising:

(A) a therapeutically effective amount of an isolated antibody or antigen-binding fragment thereof which specifically binds to Respiratory Syncytial Virus (RSV) F protein (F) and comprises:

(a) a variable heavy chain (VH) polypeptide comprising a CDRH1, a CDRH2, and a CDRH3;

(b) a variable light chain (VL) polypeptide comprising a CDRL1, a CDRL2, and a CDRL3, wherein:

(a) the amino acid sequences of the CDRH1, the CDRH2, and the CDRH3 are those contained in SEQ ID NO: 226 or comprise SEQ ID NOS: 227, 229, and 231, respectively, and

(b) the amino acid sequences of the CDRL1, the CDRL2, and the CDRL3 are those contained in SEQ ID NO: 234 or comprise SEQ ID NOS: 235, 237, and 239, respectively; and

(B) a pharmaceutically acceptable carrier and/or excipient,

with the proviso that:

(A) the amino acid sequence of the VH polypeptide is not identical to SEQ ID NO: 226; and/or

(B) the amino acid sequence of the VL polypeptide is not identical to SEQ ID NO: 234.

2. The pharmaceutical composition of claim 1 wherein:

(a) the amino acid sequence of the VH polypeptide is at least 90% identical to but is not 100% identical to SEQ ID NO: 226; and/or

(b) the amino acid sequence of the VL polypeptide is at least 90% identical to but is not 100% identical to SEQ ID NO: 234.

3. A pharmaceutical composition, comprising:

(A) a therapeutically effective amount of an isolated antibody or antigen-binding fragment thereof which specifically binds to Respiratory Syncytial Virus (RSV) F protein (F) and comprises:

(a) a heavy chain polypeptide comprising: a variable heavy chain (VH) polypeptide comprising a CDRH1, a CDRH2, and a CDRH3; and a heavy chain constant region; and

(b) a light chain polypeptide comprising: a variable light chain (VL) polypeptide comprising a CDRL1, a CDRL2, and a CDRL3; and a light chain constant region; and

(B) a pharmaceutically acceptable carrier and/or excipient,

wherein:

(a) the amino acid sequences of the CDRH1, the CDRH2, and the CDRH3 are those contained in SEQ ID NO: 226 or comprise SEQ ID NOS: 227, 229, and 231, respectively, and

(b) the amino acid sequences of the CDRL1, the CDRL2, and the CDRL3 are those contained in SEQ ID NO: 234 or comprise SEQ ID NOS: 235, 237, and 239, respectively,

and wherein the isolated antibody or antigen-binding fragment thereof is modified to eliminate effector functions.

4. A pharmaceutical composition, comprising:

(A) a therapeutically effective amount of an isolated antibody or antigen-binding fragment thereof which specifically binds to Respiratory Syncytial Virus (RSV) F protein (F) and comprises:

(a) a variable heavy chain (VH) polypeptide comprising a CDRH1, a CDRH2, and a CDRH3;

(b) a variable light chain (VL) polypeptide comprising a CDRL1, a CDRL2, and a CDRL3; and

(B) a pharmaceutically acceptable carrier and/or excipient,

wherein:

(a) the amino acid sequences of the CDRH1, the CDRH2, and the CDRH3 are those contained in SEQ ID NO: 226 or comprise SEQ ID NOS: 227, 229, and 231, respectively, and

(b) the amino acid sequences of the CDRL1, the CDRL2, and the CDRL3 are those contained in SEQ ID NO: 234 or comprise SEQ ID NOS: 235, 237, and 239, respectively,

and wherein the isolated antibody or antigen-binding fragment thereof:

(i) is one or more of: a Fab fragment; a F(ab′)2 fragment; a Fv fragment; single-chain Fv (scFv) molecule; a diabody, a triabody, a tetrabody, a minibody, and/or a small modular immunopharmaceutical (SMIP); or

(ii) comprises one or more of: single-chain Fv (scFv) molecule; a diabody, a triabody, a tetrabody, a minibody, and/or a small modular immunopharmaceutical (SMIP).

5. A pharmaceutical composition comprising:

(A) a therapeutically effective amount of an isolated antibody or antigen-binding fragment thereof which specifically binds to Respiratory Syncytial Virus (RSV) F protein (F) and comprises:

(a) a variable heavy chain (VH) polypeptide comprising a CDRH1, a CDRH2, and a CDRH3;

(b) a variable light chain (VL) polypeptide comprising a CDRL1, a CDRL2, and a CDRL3;

and

(B) a pharmaceutically acceptable carrier and/or excipient, wherein:

(a) the amino acid sequences of the CDRH1, the CDRH2, and the CDRH3 are those contained in SEQ ID NO: 226 or comprise SEQ ID NOS: 227, 229, and 231, respectively, and

(b) the amino acid sequences of the CDRL1, the CDRL2, and the CDRL3 are those contained in SEQ ID NO: 234 or comprise SEQ ID NOS: 235, 237, and 239, respectively,

and wherein the isolated antibody or antigen-binding fragment thereof is conjugated to a therapeutic moiety, wherein the therapeutic moiety comprises one or more of: an antibiotic; another anti-RSV F antibody; an anti-HMPV antibody; a vaccine; and/or a toxoid.

6. The pharmaceutical composition of claim 1 , wherein the therapeutically effective amount is about 0.1 mg to about 800 mg.

7. A pharmaceutical composition, comprising:

(A) a therapeutically effective amount of an isolated antibody or antigen-binding fragment thereof which specifically binds to Respiratory Syncytial Virus (RSV) F protein (F) and comprises:

(a) a variable heavy chain (VH) polypeptide comprising a CDRH1, a CDRH2, and a CDRH3;

(b) a variable light chain (VL) polypeptide comprising a CDRL1, a CDRL2, and a CDRL3; and

(B) a pharmaceutically acceptable carrier and/or excipient,

wherein:

(a) the amino acid sequences of the CDRH1, the CDRH2, and the CDRH3 are those contained in SEQ ID NO: 226 or comprise SEQ ID NOS: 227, 229, and 231, respectively, and

(b) the amino acid sequences of the CDRL1, the CDRL2, and the CDRL3 are those contained in SEQ ID NO: 234 or comprise SEQ ID NOS: 235, 237, and 239, respectively,

and wherein the isolated antibody or antigen-binding fragment thereof is a multi-specific antibody comprising: a first set of antigen-binding domains comprising the VH and the VL; and a second set of antigen-binding domains which specifically bind to an antigen other than RSV F.

8. The pharmaceutical composition of claim 7 , wherein the isolated antibody or antigen-binding fragment thereof is a bi-specific antibody.

9. The pharmaceutical composition of claim 8 , wherein the bi-specific antibody comprises a first CH3 domain and a second CH3 domain which differs from the first CH3 domain by at least one amino acid, wherein the at least one amino acid difference reduces binding of the bi-specific antibody to Protein A as compared to a corresponding bi-specific antibody which lacks the at least one amino acid difference.

10. The pharmaceutical composition of claim 9 , wherein the at least one amino acid difference comprises at least one amino acid substitution in the second CH3 domain relative to the first CH3 domain, wherein the at least one amino acid substitution is selected from H435R and Y436F, according to EU numbering.

11. The pharmaceutical composition of claim 10 , wherein:

(i) the bi-specific antibody is an IgG1 and the at least one amino acid substitution further comprises D356E, L358M, N384S, K392N, V397M, and/or V422I;

(ii) the bi-specific antibody is an IgG2 and the at least one amino acid substitution further comprises N384S, K392N, and/or V422I; or

(iii) the bi-specific antibody is an IgG4 and the at least one amino acid substitution further comprises Q355R, N384S, K392N, V397M, R409K, E419Q, and V422I.

12. The pharmaceutical composition of claim 3 , wherein:

(a) the amino acid sequence of the VH polypeptide is SEQ ID NO: 226 or has at least 90% identity to SEQ ID NO: 226; and/or

(b) the amino acid sequence of the VL polypeptide is SEQ ID NO: 234 or has at least 90% identity to SEQ ID NO: 234.

13. The pharmaceutical composition of claim 4 , wherein:

(a) the amino acid sequence of the VH polypeptide is SEQ ID NO: 226 or has at least 90% identity to SEQ ID NO: 226; and/or

(b) the amino acid sequence of the VL polypeptide is SEQ ID NO: 234 or has at least 90% identity to SEQ ID NO: 234.

14. The pharmaceutical composition of claim 5 , wherein:

(a) the amino acid sequence of the VH polypeptide is SEQ ID NO: 226 or has at least 90% identity to SEQ ID NO: 226; and/or

(b) the amino acid sequence of the VL polypeptide is SEQ ID NO: 234 or has at least 90% identity to SEQ ID NO: 234.

15. The pharmaceutical composition of claim 7 , wherein:

(a) the amino acid sequence of the VH polypeptide is SEQ ID NO: 226 or has at least 90% identity to SEQ ID NO: 226; and/or

(b) the amino acid sequence of the VL polypeptide is SEQ ID NO: 234 or has at least 90% identity to SEQ ID NO: 234.

Continuity (3)
Division 16343311
Provisional Application 62411508 · Oct 21, 2016
Related Publication 20230192822A1 · Jun 22, 2023
References Cited (48)
US 5866125A · Brams et al. · 1999 [cited by applicant]
US 6180370B1 · Queen · 2001 [cited by examiner]
US 9139642B2 · Williamson · 2015 [cited by examiner]
US 20020141990A1 · Deen et al. · 2002 [cited by applicant]
US 20160024188A1 · van den Brink et al. · 2016 [cited by applicant]
US 20180025435A1 · Karame et al. · 2018 [cited by applicant]
US 20190256580A1 · Walker · 2019 [cited by applicant]
US 20190256581A1 · Walker · 2019 [cited by applicant]
JP 2010534057A · 2010 [cited by applicant]
JP 2011514139A · 2011 [cited by applicant]
JP 2019521450A · 2019 [cited by applicant]
WO WO2008106980A2 · 2008 [cited by applicant]
WO WO2009030237A2 · 2009 [cited by applicant]
WO 2009088159 · 2009 [cited by applicant]
WO WO2014121021A1 · 2014 [cited by applicant]
WO WO2018075954A2 · 2018 [cited by applicant]
WO WO2018075961A1 · 2018 [cited by applicant]
WO WO2018075974A2 · 2018 [cited by applicant]
Bates, Adam, and Christine A. Power. “David vs. Goliath: the structure, function, and clinical prospects of antibody fragments.” Antibodies 8.2 (2019): 28 (Year: 2019). [cited by examiner]
Janeway, Charles A. “Immunobiology: The Immune System in Health and Disease.” 2001 (Year: 2001). [cited by examiner]
Kipriyanov, Sergey M., and Fabrice Le Gall. “Generation and production of engineered antibodies.” Molecular biotechnology 26.1 (2004): 39-60. (Year: 2004). [cited by examiner]
Janeway, Charles A., “Immunobiology: The Immune System in Health and Disease.” 2001. [cited by applicant]
Kipriyanov, Sergey M., and Fabrice Le Gall. “Generation and production of engineered antibodies.” Molecular biotechnology 26 (2004): 39-60. [cited by applicant]
Colman, Peter M. “Effects of amino acid sequence changes on antibody-antigen interactions.” Research in immunology 145.1 (1994): 33-36. [cited by applicant]
Lubert Stryer, Biochemistry, 4th, WH Freeman, New York (1995) ISBN 0-7167-2009-4 (Year: 1995). [cited by applicant]
Sela-Culang, Inbal, Vered Kunik, and Yanay Ofran. “The structural basis of antibody-antigen recognition.” Frontiers in immunology 4 (2013): 302. Year. [cited by applicant]
Gilman, Morgan SA, et al. “Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors.” Science immunology 1.6 (2016): eaaj1879. [cited by applicant]
McLellan, J. S. et al., Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody, Science, 340;1113-1117 (2013). [cited by applicant]
Casset, F. et al., A peptide mimetic of an anti-CD4 monoclonal antibody by rational design, Biochemical and Biophysical Research Communications, 307:198-205 (2003). [cited by applicant]
Huang, J. et al., Antibody Epitopes of Pneumovirus Fusion Proteins, Front Immunol, 10:2778, 8 pages (2019). [cited by applicant]
International Search Report for PCT/US17/57708 (Anti-Respiratory Syncytial Virus Antibodies, and Methods of Their Generation and Use, filed Oct. 20, 2017), issued by ISA/EP, 10 pages (Aug. 30, 2018). [cited by applicant]
International Search Report for PCT/US2017/257720 (Anti-Respiratory Syncytial Virus Antibodies, and Methods of Their Generation and Use, filed Oct. 20, 2017), issued by ISA/EPO, 10 pages (Mar. 13, 2018). [cited by applicant]
Liang, B. et al., Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate, Journal of Virology, 89(18):9499-9510 (2015). [cited by applicant]
Liang, B. et al., Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed… [cited by applicant]
Magro, M. et al., Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention, Proc Natl Acad Sci USA, 109(8):3089-94 (2012). [cited by applicant]
Mechelen, L. et al., RSV neutralization by palivizumab, but not by monoclonal antibodies targeting other epitopes, is augmented by Fc gamma receptors, Antiviral Research, 132:1-5 (2016). [cited by applicant]
Paul, William E., Fundamental Immunology, 3rd Edition, pp. 292-295 (1993). [cited by applicant]
Raghunandan, R. et al., An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immuni… [cited by applicant]
Rudikoff, S. et al., Single amino acid substitution altering antigen-binding specificity, Proc. Natl. Acad. Sci. USA, 79:1979-1983 (1982). [cited by applicant]
Written Opinion for PCT/US17/57708 (Anti-Respiratory Syncytial Virus Antibodies, and Methods of Their Generation and Use, filed Oct. 20, 2017), issued by ISA/EP, 15 pages (Aug. 30, 2018). [cited by applicant]
Written Opinion for PCT/US2017/257720 (Anti-Respiratory Syncytial Virus Antibodies, and Methods of Their Generation and Use, filed Oct. 20, 2017), issued by ISA/EPO, 12 pages (Mar. 13, 2018). [cited by applicant]
Corti, D. et al., Cross-neutralization of four paramyxoviruses by a human monoclonal antibody, Nature, 501 (7467):439-443 (2013). [cited by applicant]
Giersing, 8. et al., Meeting report: WHO consultation on Respiratory Syncytial Virus (RSV) vaccine development, Geneva, Apr. 25-26, 2016, Vaccine, 8 pages (2017). [cited by applicant]
International Search Report for PCT/US2017/057737 (Anti-Respiratory Syncytial Virus Antibodies, and Methods of Their Generation and Use, filled Oct. 20, 2017), issued by ISA/EP, 10 pages (Aug. 30, 2018). [cited by applicant]
McLellan, Jason S., Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein, Current Opinion in Virology, 11:70-75 (2015). [cited by applicant]
Ngwuta, J. et al., Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera, Science Translational Medicine, 7(309):309ra162-309ra162 (2015). [cited by applicant]
Schuster, J. et al., A Broadly Neutralizing Human Monoclonal Antibody Exhibits In Vivo Efficacy Against Both Human Metapneumovirus and Respiratory Syncytial Virus, Journal of Infectious Diseases, 211(2):216-225 (2014). [cited by applicant]
Written Opinion for PCT/US2017/057737 (Anti-Respiratory Syncytial Virus Antibodies, and Methods of Their Generation and Use, filed Oct. 20, 2017), issued by ISA/EP. 14 pages (Aug. 30, 2018). [cited by applicant]